XGN

Exagen Inc. (XGN) | Rumor.io

Exagen

XGN

Attention (50-day avg)0%

Attention rank (50-day avg)#1,570

Bullish sentiment (50-day avg)98%

Price to earnings ratio-9.11

Market capitalization205.4M

Earnings per share-0.82

Dividend yield (TTM)—

Revenue (annual)66.6M

Net income (annual)-20M

Social

What share of all stock conversation is about XGN?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% +0	0% 0	0% 0

Aug 4

Exagen Inc. (XGN) reported record total revenue of $19.9 million in Q2 2026, a 16% increase YoY, and adjusted EBITDA loss narrowed to -$0.1 million.
XGN's revenue growth and profitability improvements were driven by a 4% ASP increase and accelerating revenue.
Exagen Inc. increased its full-year 2026 revenue guidance to $72 million to $75 million, and its Q2 2026 earnings were highlighted by a record revenue breakout.

Generated by AI

Sentiment

Of the messages about XGN that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	100%	100%	100% +2.08	92.08% -5.19
Bearish	0%	0%	0% -2.08	7.92% +5.19

Bullish· Jun 10

Exagen Inc. ($XGN) is expected to see a potential 130% upside in wave 3, following a pullback to the 50-day moving average (DMA) and 0.618 Fibonacci (fib) level.
The price has completed subwave 1 and is now pulling back for subwave 2, setting up a potential buying opportunity at the 50DMA and 0.618 fib confluence.
A pullback to the 50DMA and 0.618 fib level is seen as a buy zone for Exagen Inc. ($XGN), with a target of 130% gains in subwave 3.

Bearish· Nov 25

$XGN is experiencing a strong short squeeze, with shorts being squeezed out.
The asset's price is expected to fall further, potentially by 5-10% if it breaks below $4.
The company's financials are a mixed bag, with some positive signs such as legitimate medical testing and increased delivery volumes, but also some red flags like accounting mistakes and adjusted revenue down.

Generated by AI

Topics

Of the messages about XGN that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Technical Analysis	—	100%	100%	24.26%
Announcements	—	0%	0%	66.89%
Earnings	—	0%	0%	6.35%
Analysts	—	0%	0%	2.49%
Controversies	—	0%	0%	0%
Macro	—	0%	0%	0%

Jun 10

Exagen Inc.'s (XGN) price has completed subwave 1 and is pulling back for subwave 2, with a target of 130% gain in subwave 3.
The 50-day moving average (50DMA) and 0.618 Fibonacci level are key levels to watch for a potential entry point in XGN.
XGN's price is unfolding exactly as expected, with wave 1 complete and wave 2 in progress, setting up a potential 130%+ upside in wave 3.

Generated by AI

Community

Of the messages about XGN, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	100%	88.68%	93.9%	25.89%
Newcomers	0%	11.32%	6.1%	74.11%

Regulars· Mar 22

Exagen has expanded its in-network benefit to an additional 22.7 million lives, potentially increasing its reach in the healthcare market.
The company reported a GAAP EPS of -$0.42, beating the consensus estimate of -$0.49, and revenue of $12.69M, which also beat expectations.
Exagen's revenue grew by 13.70% year-over-year, ranking 2123 out of 5722 companies in the database, and the company has reported its fourth quarter and full year 2021 results.

Newcomers· Aug 4

Breakout above $7, with some users speculating on what happens next.
Exagen Inc. reported record total revenue of $19.9 million in the 2nd quarter of 2026, exceeding analysts' estimates by 16%.
The stock has seen significant price increases, with some users noting it has already hit $6.45 and is now at $6.4, with some speculating on potential future price movements.

Generated by AI

News

Exagen (XGN) Receives a Buy from Roth MKM

Detailed price information for Exagen Inc (XGN-Q) from The Globe and Mail including charting and trades.

6d agoThe Globe and Mail

Full Transcript: Exagen Q2 2026 Earnings Call

13d agoBenzinga

Exagen at Canaccord Genuity growth conference: turnaround gains pace

1mo agoInvesting.com

Exagen (XGN) Q2 2026 Earnings Call Transcript

Detailed price information for Exagen Inc (XGN-Q) from The Globe and Mail including charting and trades.

1mo agoThe Globe and Mail

Analysts Have Conflicting Sentiments on These Healthcare Companies: Pfizer (PFE), Exagen (XGN) and Warby Parker (WRBY)

Detailed price information for Pfizer Inc (PFE-N) from The Globe and Mail including charting and trades.

1mo agoThe Globe and Mail

Analysts Offer Insights on Healthcare Companies: Exagen (XGN), Amgen (AMGN) and Arvinas Holding Company (ARVN)

Detailed price information for Exagen Inc (XGN-Q) from The Globe and Mail including charting and trades.

1mo agoThe Globe and Mail

Also Discussed

Investors talking about XGN also mention

#	Name	Attention
1	Porch Group, Inc.PRCH	0%0
2	Wearable Devices Ltd.WLDS	0%+0
3	REGI - Renewable Energy Group, Inc.	——
4	OCFT - OneConnect Financial Technology Co., Ltd.	——
5	Rayonier Advanced Materials Inc.RYAM	0%new
6	The Oncology Institute Inc.TOI	0%new
7	Apyx Medical CorporationAPYX	0%new
8	Quoin Pharmaceuticals, Ltd. American Depositary SharesQNRX	0%0
9	GCT Semiconductor Holding, Inc.GCTS	0.01%+0
10	Alzamend Neuro, Inc.ALZN	0%0

Exagen Inc.

Healthcare
Diagnostics & Research

Exagen Inc. is a commercial-stage diagnostics company specializing in autoimmune testing solutions under the AVISE brand in the United States. It designs, develops, and commercializes testing products that enable healthcare providers to diagnose, prognose, and monitor complex rheumatic and autoimmune diseases, such as systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), and other connective tissue diseases (CTDs). The lead product, AVISE CTD, supports differential diagnosis for patients with overlapping symptoms of various CTDs. Exagen Inc. also offers specialized biomarkers, including those for seronegative rheumatoid arthritis like anti-PAD4 markers and urinary panels for lupus nephritis, enhancing clinical utility in rheumatology. These tests play a key role in improving patient care by facilitating timely interventions and optimizing therapeutic strategies within the autoimmune diagnostics market. Headquartered in Carlsbad, California, Exagen Inc. focuses on advancing laboratory testing adoption among rheumatologists and supports research through presentations at medical conferences.

Website

Location

1261 Liberty Way

Vista, CA, 92081

United States

Social

What share of all stock conversation is about XGN?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% +0	0% 0	0% 0

Aug 4

Exagen Inc. (XGN) reported record total revenue of $19.9 million in Q2 2026, a 16% increase YoY, and adjusted EBITDA loss narrowed to -$0.1 million.
XGN's revenue growth and profitability improvements were driven by a 4% ASP increase and accelerating revenue.
Exagen Inc. increased its full-year 2026 revenue guidance to $72 million to $75 million, and its Q2 2026 earnings were highlighted by a record revenue breakout.

Generated by AI

Sentiment

Of the messages about XGN that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	100%	100%	100% +2.08	92.08% -5.19
Bearish	0%	0%	0% -2.08	7.92% +5.19

Bullish· Jun 10

Exagen Inc. ($XGN) is expected to see a potential 130% upside in wave 3, following a pullback to the 50-day moving average (DMA) and 0.618 Fibonacci (fib) level.
The price has completed subwave 1 and is now pulling back for subwave 2, setting up a potential buying opportunity at the 50DMA and 0.618 fib confluence.
A pullback to the 50DMA and 0.618 fib level is seen as a buy zone for Exagen Inc. ($XGN), with a target of 130% gains in subwave 3.

Bearish· Nov 25

$XGN is experiencing a strong short squeeze, with shorts being squeezed out.
The asset's price is expected to fall further, potentially by 5-10% if it breaks below $4.
The company's financials are a mixed bag, with some positive signs such as legitimate medical testing and increased delivery volumes, but also some red flags like accounting mistakes and adjusted revenue down.

Generated by AI

Topics

Of the messages about XGN that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Technical Analysis	—	100%	100%	24.26%
Announcements	—	0%	0%	66.89%
Earnings	—	0%	0%	6.35%
Analysts	—	0%	0%	2.49%
Controversies	—	0%	0%	0%
Macro	—	0%	0%	0%

Jun 10

Exagen Inc.'s (XGN) price has completed subwave 1 and is pulling back for subwave 2, with a target of 130% gain in subwave 3.
The 50-day moving average (50DMA) and 0.618 Fibonacci level are key levels to watch for a potential entry point in XGN.
XGN's price is unfolding exactly as expected, with wave 1 complete and wave 2 in progress, setting up a potential 130%+ upside in wave 3.

Generated by AI

Community

Of the messages about XGN, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	100%	88.68%	93.9%	25.89%
Newcomers	0%	11.32%	6.1%	74.11%

Regulars· Mar 22

Exagen has expanded its in-network benefit to an additional 22.7 million lives, potentially increasing its reach in the healthcare market.
The company reported a GAAP EPS of -$0.42, beating the consensus estimate of -$0.49, and revenue of $12.69M, which also beat expectations.
Exagen's revenue grew by 13.70% year-over-year, ranking 2123 out of 5722 companies in the database, and the company has reported its fourth quarter and full year 2021 results.

Newcomers· Aug 4

Breakout above $7, with some users speculating on what happens next.
Exagen Inc. reported record total revenue of $19.9 million in the 2nd quarter of 2026, exceeding analysts' estimates by 16%.
The stock has seen significant price increases, with some users noting it has already hit $6.45 and is now at $6.4, with some speculating on potential future price movements.

Generated by AI

Exagen

Social

Aug 4

Bullish· Jun 10

Bearish· Nov 25

Jun 10

Regulars· Mar 22

Newcomers· Aug 4

Exagen (XGN) Receives a Buy from Roth MKM

Full Transcript: Exagen Q2 2026 Earnings Call

Exagen at Canaccord Genuity growth conference: turnaround gains pace

Exagen (XGN) Q2 2026 Earnings Call Transcript

Analysts Have Conflicting Sentiments on These Healthcare Companies: Pfizer (PFE), Exagen (XGN) and Warby Parker (WRBY)

Analysts Offer Insights on Healthcare Companies: Exagen (XGN), Amgen (AMGN) and Arvinas Holding Company (ARVN)

Also Discussed

Exagen Inc.

Company Information

Location

Social

Aug 4

Bullish· Jun 10

Bearish· Nov 25

Jun 10

Regulars· Mar 22

Newcomers· Aug 4

Exagen (XGN) Receives a Buy from Roth MKM

Full Transcript: Exagen Q2 2026 Earnings Call

Exagen at Canaccord Genuity growth conference: turnaround gains pace

Exagen (XGN) Q2 2026 Earnings Call Transcript

Analysts Have Conflicting Sentiments on These Healthcare Companies: Pfizer (PFE), Exagen (XGN) and Warby Parker (WRBY)

Analysts Offer Insights on Healthcare Companies: Exagen (XGN), Amgen (AMGN) and Arvinas Holding Company (ARVN)

Also Discussed